Lintner Nathanael G, McClure Kim F, Petersen Donna, Londregan Allyn T, Piotrowski David W, Wei Liuqing, Xiao Jun, Bolt Michael, Loria Paula M, Maguire Bruce, Geoghegan Kieran F, Huang Austin, Rolph Tim, Liras Spiros, Doudna Jennifer A, Dullea Robert G, Cate Jamie H D
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, United States of America.
Pfizer Medicinal Chemistry, Cardiovascular, Metabolic and Endocrine Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
PLoS Biol. 2017 Mar 21;15(3):e2001882. doi: 10.1371/journal.pbio.2001882. eCollection 2017 Mar.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small molecules to specifically block translation of individual transcripts.
前蛋白转化酶枯草溶菌素/凯新9型(PCSK9)在调节血浆低密度脂蛋白胆固醇(LDL-C)水平方面发挥着关键作用。在此,我们证明化合物PF-06446846通过诱导核糖体在密码子34附近停滞来抑制PCSK9的翻译,这是由新生链在出口通道内的序列介导的。我们进一步表明,口服给药后,PF-06446846可降低大鼠血浆中PCSK9和总胆固醇水平。利用核糖体分析,我们证明PF-06446846对抑制PCSK9翻译具有高度选择性。PF-06446846所采用的作用机制揭示了人类核糖体此前未被发现的可调节性,即小分子能够特异性地阻断单个转录本的翻译。